Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13-PE38QQR in Recurrent Malignant Glioma
NCT00024570Phase 2Completed
- Sponsor
- Insys Therapeutics
- Start
- Nov 2000
- Primary completion
- Jul 2007
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of cintredekin besudotox in malignant glioma, glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), oligoastrocytoma (OA), sponsored by Insys Therapeutics. Started Nov 2000; status: completed.
02
Drugs
cintredekin besudotox
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)anaplastic astrocytoma (AA)oligoastrocytoma (OA)
Beyond the preview
Go deeper on NCT00024570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024570.